Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

J D, VC DMaio, De Salazar A, et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol [Internet]. 2021;74(4):801-810. https://doi.org/10.1016/j.jhep.2020.11.017

Publication Type:

Journal Article

Authors:

Dietz J; Di Maio VC; De Salazar, A; et, al

Source:

J Hepatol, Volume 74, Issue 4, p.801-810 (2021)

URL:

https://doi.org/10.1016/j.jhep.2020.11.017

Keywords:

DAA, Direct-acting antivirals, HCV, hepatitis C virus, Rescue therapy, Resistance-Associated Substitutions, Voxilaprevir/velpatasvir/sofosbuvir

Cited On:

Multiple DAA Treatment Failures (All Genotypes), Including Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir Plus Glecaprevir/Pibrentasvir

External Third-party Web Link:

https://pubmed.ncbi.nlm.nih.gov/33220331/

Export Citation:

RIS Format

Top